Articles

Find an Article

Filter articles

Showing 21 to 30 of 744 results

UN International Day of Women and Girls in Science: a perspective

International10-02-2022Chiara Banas

Chiara Banas, patent scientist at EIP, queries the gender gap in life sciences, and shares how her own experiences could prefigure change.

Why mentorship matters

International25-01-2022Muireann Bolger

Effective support and guidance can achieve greater diversity in life sciences, say general counsel from Bristol Myers Squibb, AstraZeneca, The Chemours Company and Eli Lilly.

Pandemic blues: the global approach to COVID-related IP

US20-01-2022Matthew Howell and Lauren Griffin

While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

A guide for life sciences entrepreneurs

International22-12-2021Chad Shear

Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.

Psychedelics: from fungi and plants to patents

US30-09-2021Gretchen Temeles & Timothy Schlidt

With the significant growth of cannabinoid IP in the past few years, eyes are now on the emerging psychedelics market as the next frontier for IP protection. Gretchen Temeles of Hiller and Timothy Schlidt of Palo Santo Ventures discuss the issues.

Mexico: New hurdles for plant rights owners

Mexico23-09-2021Corina Silva

Mexico’s updated IP laws seek to avoid the patentability of plants obtained by essentially biological processes—creating issues for plant rights owners, explains Corina Silva of Uhthoff, Gómez Vega & Uhthoff.

Amendments to Chinese Patents Law for the Life Sciences

China09-09-2021Keith Haddaway and Christopher Loh

Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.

NHS v Servier: unlawful means tort claim fails, but the long-running saga continues

UK17-08-2021Beatriz San Martin and Shishu Chen

The latest episode in the long-running dispute between the NHS and French pharmaceutical company Servier has been marked by a UK Supreme Court judgment of July 2, 2021 on Servier’s application to strike out the NHS’s unlawful means tort claim.

A new drug pricing system reform proposal in Japan

Japan17-08-2021Takanori Abe

A Japanese think tank is recommending an overhaul of Japan’s drug pricing system. Takanori Abe of Abe and Partners reports.

UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver

EU10-08-2021Sophie Topham

In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.

Showing 21 to 30 of 744 results

LSIPR